$CLDX
Celldex Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000110465922087222 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $407.0K $163.0K $174.0K
YoY Change 166.01% -95.32% -74.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.531M $7.154M $6.911M
YoY Change 12.2% 66.14% 67.74%
% of Gross Profit
Research & Development $21.57M $20.73M $17.06M
YoY Change 59.12% 67.78% 34.09%
% of Gross Profit
Depreciation & Amortization $671.0K $741.0K $811.0K
YoY Change -10.77% -2.37% 4.65%
% of Gross Profit
Operating Expenses $21.57M $20.73M $17.06M
YoY Change 59.12% 67.78% 34.09%
Operating Profit -$27.70M -$36.40M -$23.26M
YoY Change 33.0% 170.8% 39.77%
Interest Expense $912.0K $392.0K $207.0K
YoY Change 528.97% 485.07% 107.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.78M -$36.00M -$23.05M
YoY Change 29.52% 169.23% 39.38%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$26.78M -$36.00M -$23.05M
YoY Change 30.96% 169.23% 39.36%
Net Earnings / Revenue -6580.84% -22088.34% -13247.13%
Basic Earnings Per Share -$0.57 -$0.77 -$0.49
Diluted Earnings Per Share -$0.57 -$0.77 -$0.49
COMMON SHARES
Basic Shares Outstanding 46.77M 46.76M 46.74M
Diluted Shares Outstanding 46.92M 46.76M 46.74M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $323.5M $356.8M $380.5M
YoY Change -23.55% 117.52% 116.05%
Cash & Equivalents $18.58M $28.40M $25.29M
Short-Term Investments $304.9M $328.4M $355.2M
Other Short-Term Assets $10.94M $11.07M $9.988M
YoY Change 234.63% 260.07% 177.44%
Inventory
Prepaid Expenses
Receivables $189.0K $97.00K $243.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $334.6M $368.0M $390.7M
YoY Change -21.56% 119.55% 115.26%
LONG-TERM ASSETS
Property, Plant & Equipment $3.753M $3.744M $3.484M
YoY Change 12.3% 7.09% -48.76%
Goodwill
YoY Change
Intangibles $27.19M $27.19M $27.19M
YoY Change 0.0% -11.4%
Long-Term Investments
YoY Change
Other Assets $104.0K $104.0K $104.0K
YoY Change 6.12% 153.66%
Total Long-Term Assets $34.63M $34.98M $33.34M
YoY Change 2.92% -5.31% -11.32%
TOTAL ASSETS
Total Short-Term Assets $334.6M $368.0M $390.7M
Total Long-Term Assets $34.63M $34.98M $33.34M
Total Assets $369.2M $403.0M $424.0M
YoY Change -19.77% 97.0% 93.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.272M $902.0K $1.019M
YoY Change 171.77% 31.68% 1.9%
Accrued Expenses $11.43M $11.23M $9.234M
YoY Change 11.43% 43.03% 9.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.29M $29.95M $14.56M
YoY Change 14.89% 106.72% -14.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.333M $5.333M $10.54M
YoY Change -29.83% -15.82% 72.77%
Total Long-Term Liabilities $5.333M $5.333M $10.54M
YoY Change -29.83% -15.82% 72.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.29M $29.95M $14.56M
Total Long-Term Liabilities $5.333M $5.333M $10.54M
Total Liabilities $23.81M $37.87M $25.94M
YoY Change 1.37% 70.05% 4.18%
SHAREHOLDERS EQUITY
Retained Earnings -$1.229B -$1.203B -$1.167B
YoY Change 9.43% 9.03%
Common Stock $1.575B $1.568B $1.565B
YoY Change 1.11% 22.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.4M $365.1M $398.1M
YoY Change
Total Liabilities & Shareholders Equity $369.2M $403.0M $424.0M
YoY Change -19.77% 97.0% 93.54%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$26.78M -$36.00M -$23.05M
YoY Change 30.96% 169.23% 39.36%
Depreciation, Depletion And Amortization $671.0K $741.0K $811.0K
YoY Change -10.77% -2.37% 4.65%
Cash From Operating Activities -$35.19M -$22.24M -$24.50M
YoY Change 114.95% 86.39% 35.48%
INVESTING ACTIVITIES
Capital Expenditures -$345.0K -$673.0K $575.0K
YoY Change 86.49% 380.71% 1.41%
Acquisitions
YoY Change
Other Investing Activities $23.41M $25.95M $10.96M
YoY Change -110.33% -288.55% -75.13%
Cash From Investing Activities $23.07M $25.28M $10.38M
YoY Change -110.17% -281.68% -76.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.306M 71.00K 304.0K
YoY Change -99.15% -438.1% 310.81%
NET CHANGE
Cash From Operating Activities -35.19M -22.24M -24.50M
Cash From Investing Activities 23.07M 25.28M 10.38M
Cash From Financing Activities 2.306M 71.00K 304.0K
Net Change In Cash -9.818M 3.108M -13.85M
YoY Change -134.16% -112.01% -154.36%
FREE CASH FLOW
Cash From Operating Activities -$35.19M -$22.24M -$24.50M
Capital Expenditures -$345.0K -$673.0K $575.0K
Free Cash Flow -$34.85M -$21.57M -$25.08M
YoY Change 115.28% 82.9% 34.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29911000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46759000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39616000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46749000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39615000
dei Entity Central Index Key
EntityCentralIndexKey
0000744218
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46764703
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46730198
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-15006
dei Entity Registrant Name
EntityRegistrantName
CELLDEX THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3191702
dei Entity Address Address Line1
EntityAddressAddressLine1
Perryville III Building
dei Entity Address Address Line2
EntityAddressAddressLine2
53 Frontage Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Hampton
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08827
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
200-7500
dei Security12b Title
Security12bTitle
Common Stock, par value $.001
dei Trading Symbol
TradingSymbol
CLDX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46772351
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28401000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39143000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
328416000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59054000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29911000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-529000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36533000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2311000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12000000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13368000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61365000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
369107000
CY2022Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
97000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
172000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11065000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2417000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
367979000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
410839000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3744000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3551000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3944000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2970000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27190000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
27190000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
104000
CY2022Q2 us-gaap Assets
Assets
402961000
CY2021Q4 us-gaap Assets
Assets
444654000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
902000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1228000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11229000
CY2022Q2 cldx Litigation Settlement Payable
LitigationSettlementPayable
15000000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1425000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1746000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1393000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1554000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29949000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16528000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2586000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1296000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5333000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7354000
CY2022Q2 us-gaap Liabilities
Liabilities
37868000
CY2021Q4 us-gaap Liabilities
Liabilities
25178000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
3000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
297000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46764703
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46730198
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
47000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29908000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59054000
us-gaap Costs And Expenses
CostsAndExpenses
59990000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1568124000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1561142000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-417000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1894000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1202661000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1143607000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
365093000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
419476000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
402961000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
444654000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
163000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3480000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
337000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4165000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20731000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12356000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37786000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25076000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7154000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4306000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14066000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8426000
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
6326000
CY2021Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-258000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
6862000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-741000
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-15000000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-15000000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
36559000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
16920000
us-gaap Costs And Expenses
CostsAndExpenses
34243000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-36396000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13440000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59653000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30078000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
392000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
67000
us-gaap Interest And Other Income
InterestAndOtherIncome
599000
us-gaap Interest And Other Income
InterestAndOtherIncome
167000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36004000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13373000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59054000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29911000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46759000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39616000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46749000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39615000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36004000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13373000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43446000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43836000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28401000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1552000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1539000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1308000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
173000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-57000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
6862000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-741000
us-gaap Share Based Compensation
ShareBasedCompensation
6607000
us-gaap Share Based Compensation
ShareBasedCompensation
2784000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-75000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1306000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8485000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1544000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-862000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-750000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
15000000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3886000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3982000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46778000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30014000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
106756000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
116000000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69847000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
85739000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1248000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
710000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
24000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35661000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29575000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
375000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
49000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
375000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10742000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-390000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39143000
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
54000
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(1)  Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics, Inc. (the “Company” or “Celldex”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2022. In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company’s financial position and results of operations for the interim periods presented. The year-end condensed balance sheet data presented for comparative purposes was derived from audited financial statements but does not include all disclosures required by U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">At June 30, 2022, the Company had cash, cash equivalents and marketable securities of $356.8 million. The Company has had recurring losses and incurred a loss of $59.1 million for the six months ended June 30, 2022. Net cash used in operations for the six months ended June 30, 2022 was $46.8 million. The Company believes that the cash, cash equivalents and marketable securities at the filing date of this Form 10-Q will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months from the date of issuance of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the next twelve months and beyond, the Company may take further steps to raise additional capital to meet its long-term liquidity needs including, but not limited to, one or more of the following: the licensing of drug candidates with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. Although the Company has been successful in raising capital in the past, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company’s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financings may be dilutive to the Company’s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company’s economic potential from products under development. The Company’s ability to continue funding its planned operations beyond twelve months from the issuance date is also dependent on the timing and manner of payment of amounts due under the Settlement Agreement with Shareholder Representative Services LLC (“SRS”) (refer to Note 13), in the event that the Company achieves the milestones related to those payments. The Company, at its option, may decide to pay those milestone payments in cash, shares of its common stock or a combination thereof. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay ongoing or anticipated clinical trials, license out programs earlier than expected, raise funds at a significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The COVID-19 pandemic continues to have a major impact in the US and around the world. The availability of vaccines holds promise for the future, though new variants of the virus and potential waning immunity from vaccines may result in continued impact from this pandemic in the future, which could adversely impact our operations. To date, we have managed delays and disruptions without significant impact in planned and ongoing preclinical and clinical trials, manufacturing or shipping. Potential impacts to our business include delays in planned and ongoing preclinical and clinical trials including enrollment of patients, disruptions in time and resources provided by independent clinical investigators, contract research organizations, and other third-party service providers, temporary closures of our facilities, disruptions or restrictions on our employees’ ability to travel, and delays in manufacturing and/or shipments to and from third-party suppliers and contract manufacturers for APIs and drug product. Any prolonged negative impacts to our business could materially impact our operating results and could lead to impairments of our intangible in-process research and development (“IPR&amp;D”) assets with a carrying value of $27.2 million at June 30, 2022.</p>
CY2022Q2 us-gaap Investments And Cash
InvestmentsAndCash
356800000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-59100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46800000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
331429000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3013000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
328416000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
6900000
CY2021Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-300000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-700000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
419476000
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
6300000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
369809000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
702000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
369107000
CY2022Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2021Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q2 us-gaap Interest Receivable
InterestReceivable
1100000
CY2021Q4 us-gaap Interest Receivable
InterestReceivable
1300000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
304000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2784000
CY2022Q2 cldx Deferred Income From Sale Of Tax Benefits
DeferredIncomeFromSaleOfTaxBenefits
4650000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
6862000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
27200000
CY2022Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1613000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
463000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
433000
CY2022Q2 us-gaap Other Liabilities
OtherLiabilities
6726000
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
8908000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1393000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1554000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5333000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7354000
CY2022Q2 cldx Stock Issued Remaining Authorized Amount
StockIssuedRemainingAuthorizedAmount
50000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
48600000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26200000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
51200000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3153000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1782000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23050000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
398101000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
71000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3454000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-529000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36004000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
365093000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
209357000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
74000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1275000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16538000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
194166000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
25000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1509000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13373000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
182282000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.29
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3454000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1509000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6607000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
400000
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
200000
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5590213
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4344622
CY2022Q2 cldx Business Combination Contingent Consideration Settlement Agreement Amount Paid
BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid
15000000
CY2022Q2 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1600000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1600000

Files In Submission

Name View Source Status
0001104659-22-087222-index-headers.html Edgar Link pending
0001104659-22-087222-index.html Edgar Link pending
0001104659-22-087222.txt Edgar Link pending
0001104659-22-087222-xbrl.zip Edgar Link pending
cldx-20220630.xsd Edgar Link pending
cldx-20220630x10q.htm Edgar Link pending
cldx-20220630xex10d3.htm Edgar Link pending
cldx-20220630xex31d1.htm Edgar Link pending
cldx-20220630xex31d2.htm Edgar Link pending
cldx-20220630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
cldx-20220630_cal.xml Edgar Link unprocessable
cldx-20220630_def.xml Edgar Link unprocessable
cldx-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cldx-20220630_pre.xml Edgar Link unprocessable
cldx-20220630x10q_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending